دورية أكاديمية
Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment.
| العنوان: | Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment. |
|---|---|
| المؤلفون: | Silva AJD; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Moura IA; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Gama MATMD; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Leal LRS; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Pinho SS; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Espinoza BCF; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Santos DLD; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Santos VEP; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Sena MGAM; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Invenção MDCV; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Macêdo LS; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., França Neto PL; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Freitas AC; Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil. |
| المصدر: | Vaccines [Vaccines (Basel)] 2023 Aug 11; Vol. 11 (8). Date of Electronic Publication: 2023 Aug 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG |
| مستخلص: | The understanding of the relationship between immunological responses and cancers, especially those related to HPV, has allowed for the study and development of therapeutic vaccines against these neoplasias. There is a growing number of studies about the composition and influence of the tumor microenvironment (TME) in the progression or establishment of the most varied types of cancer. Hence, it has been possible to structure immunotherapy approaches based on therapeutic vaccines that are even more specific and directed to components of TME and the immune response associated with tumors. Among these components are dendritic cells (DCs), which are the main professional antigen-presenting cells (APCs) already studied in therapy strategies for HPV-related cancers. On the other hand, tumor-associated macrophages are also potential targets since the profile present in tumor infiltrates, M1 or M2, influences the prognosis of some types of cancer. These two cell types can be targets for therapy or immunomodulation. In this context, our review aims to provide an overview of immunotherapy strategies for HPV-positive tumors, such as cervical and head and neck cancers, pointing to TME immune cells as promising targets for these approaches. This review also explores the potential of immunotherapy in cancer treatment, including checkpoint inhibitors, cytokine immunotherapies, immunotherapy vaccines, and cell therapies. Furthermore, it highlights the importance of understanding the TME and its effect on the design and achievement of immunotherapeutic methods. |
| References: | BMC Cancer. 2019 Jan 14;19(1):61. (PMID: 30642295) Curr Probl Cancer. 2018 Mar - Apr;42(2):129-136. (PMID: 29428790) Immune Netw. 2020 Mar 09;20(2):e14. (PMID: 32395366) Cancer Manag Res. 2019 Jun 05;11:5171-5185. (PMID: 31239772) Cancer Res. 2019 Sep 15;79(18):4557-4566. (PMID: 31350295) Nat Rev Immunol. 2020 Jan;20(1):7-24. (PMID: 31467405) J Mol Med (Berl). 2022 Jun;100(6):829-845. (PMID: 35478255) J Immunol. 2014 Jun 15;192(12):5451-8. (PMID: 24907378) J Immunother. 2021 Oct 1;44(8):292-306. (PMID: 34432728) Clin Cancer Res. 2016 May 1;22(9):2155-66. (PMID: 26712687) Cancers (Basel). 2020 Apr 25;12(5):. (PMID: 32344813) Cancer Treat Rev. 2019 Aug;78:8-16. (PMID: 31302573) Nat Rev Immunol. 2018 Mar;18(3):168-182. (PMID: 29226910) Semin Oncol Nurs. 2019 Oct;35(5):150923. (PMID: 31526550) Cancer Cell. 2023 Feb 13;41(2):356-372.e10. (PMID: 36706760) Viruses. 2021 Feb 20;13(2):. (PMID: 33672465) Front Cell Dev Biol. 2021 Jun 28;9:686544. (PMID: 34262904) Lancet. 2007 Jun 2;369(9576):1861-1868. (PMID: 17544766) Front Oncol. 2016 Jan 08;5:298. (PMID: 26779441) Immunology. 2013 Aug;139(4):513-22. (PMID: 23521696) J Clin Oncol. 2010 Nov 1;28(31):4706-13. (PMID: 20921462) Front Immunol. 2013 Dec 03;4:417. (PMID: 24348481) Cancer Lett. 2020 Feb 28;471:88-102. (PMID: 31812696) Front Cell Infect Microbiol. 2022 Jul 04;12:909223. (PMID: 35860379) J Infect Dev Ctries. 2021 May 31;15(5):719-725. (PMID: 34106897) Cancer Lett. 2021 Jan 28;497:243-254. (PMID: 33122098) PLoS One. 2015 Sep 03;10(9):e0136654. (PMID: 26335330) Cancer Treat Rev. 2015 Dec;41(10):844-52. (PMID: 26476574) Head Neck. 2020 Aug;42(8):2194-2201. (PMID: 32220043) Cancers (Basel). 2022 Dec 23;15(1):. (PMID: 36612102) Front Mol Biosci. 2020 Jan 31;6:160. (PMID: 32118030) Int J Oncol. 2013 Oct;43(4):1151-9. (PMID: 23877655) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Vaccines (Basel). 2021 Dec 31;10(1):. (PMID: 35062714) Nat Rev Immunol. 2012 Jul 13;12(8):557-69. (PMID: 22790179) Cancers (Basel). 2023 Apr 13;15(8):. (PMID: 37190214) Lancet Oncol. 2022 Jul;23(7):940-949. (PMID: 35709811) Lancet Oncol. 2020 Dec;21(12):1653-1660. (PMID: 33271094) Invest Ophthalmol Vis Sci. 2021 Nov 1;62(14):11. (PMID: 34779821) J Cancer Res Clin Oncol. 2018 Dec;144(12):2367-2376. (PMID: 30225539) Cancers (Basel). 2020 Mar 05;12(3):. (PMID: 32150821) Cell. 2018 Dec 13;175(7):1731-1743.e13. (PMID: 30503213) Pathogens. 2022 Nov 30;11(12):. (PMID: 36558778) Oncol Res. 2023 Jan 12;30(3):99-116. (PMID: 37305016) Oncotarget. 2016 Aug 9;7(32):52294-52306. (PMID: 27418133) Oral Oncol. 2022 Dec;135:106227. (PMID: 36335818) Antiviral Res. 2020 Jun;178:104794. (PMID: 32298665) JAMA Oncol. 2023 Jun 1;9(6):779-789. (PMID: 37022706) Transl Cancer Res. 2020 Mar;9(3):2026-2036. (PMID: 35117549) Semin Radiat Oncol. 2021 Oct;31(4):361-370. (PMID: 34455991) Nat Med. 2021 Mar;27(3):419-425. (PMID: 33558725) Gynecol Oncol Rep. 2022 Jul 08;42:101039. (PMID: 35846558) Cancer Immunol Immunother. 2017 Jan;66(1):51-61. (PMID: 27783105) Int J Mol Sci. 2020 Aug 01;21(15):. (PMID: 32752264) Open Virol J. 2012;6:249-56. (PMID: 23341860) J Clin Oncol. 2007 Jun 1;25(16):2171-7. (PMID: 17538161) J Immunother Cancer. 2018 Mar 23;6(1):23. (PMID: 29566749) Lancet Oncol. 2019 Jan;20(1):145-158. (PMID: 30573285) Front Med (Lausanne). 2021 Nov 22;8:756029. (PMID: 34881261) J Hematol Oncol. 2021 Oct 30;14(1):181. (PMID: 34717710) J Immunol Res. 2018 Mar 14;2018:9585614. (PMID: 29725606) Eur Urol. 2022 Jun;81(6):570-573. (PMID: 35183395) J Gynecol Oncol. 2016 Sep;27(5):e51. (PMID: 27329199) J Control Release. 2020 Sep 10;325:235-248. (PMID: 32649972) Rep Pract Oncol Radiother. 2019 Nov-Dec;24(6):544-550. (PMID: 31641340) Semin Immunol. 2023 Jan;65:101671. (PMID: 36459926) Curr Oncol Rep. 2018 Mar 3;20(2):22. (PMID: 29502288) Cancer Cell Int. 2021 Sep 7;21(1):473. (PMID: 34493268) Breast Cancer (Auckl). 2015 Dec 10;9:93-7. (PMID: 26691275) Cancer. 2015 Feb 15;121(4):545-55. (PMID: 25336438) Cell. 2018 Aug 23;174(5):1293-1308.e36. (PMID: 29961579) Iran J Microbiol. 2012 Dec;4(4):187-90. (PMID: 23205250) J Immunol. 2015 Nov 15;195(10):5055-65. (PMID: 26453753) Virus Res. 2017 Mar 2;231:21-33. (PMID: 27890631) Ann Transl Med. 2020 Jul;8(13):813. (PMID: 32793658) J Laryngol Otol. 2007 Mar;121(3):246-52. (PMID: 17040593) Lancet. 2014 Sep 20;384(9948):1109-17. (PMID: 25034862) Front Immunol. 2021 Jun 01;12:690499. (PMID: 34140957) Cancers (Basel). 2023 Jan 28;15(3):. (PMID: 36765760) Clin Cancer Res. 2020 Apr 1;26(7):1616-1623. (PMID: 31727676) Nat Rev Drug Discov. 2020 Mar;19(3):200-218. (PMID: 31907401) Front Immunol. 2020 Oct 09;11:565683. (PMID: 33162980) Diagn Pathol. 2013 Apr 15;8:61. (PMID: 23587428) Front Immunol. 2019 Jul 23;10:1676. (PMID: 31396215) Mol Ther Oncolytics. 2021 Jul 21;22:410-430. (PMID: 34553029) Virus Res. 2017 Mar 2;231:119-127. (PMID: 28040475) Hum Immunol. 2018 Dec;79(12):876-882. (PMID: 30261221) Am J Pathol. 1997 Apr;150(4):1327-33. (PMID: 9094989) Cancers (Basel). 2022 Jun 11;14(12):. (PMID: 35740551) Cancers (Basel). 2022 Oct 29;14(21):. (PMID: 36358752) Br J Cancer. 2020 Feb;122(3):306-314. (PMID: 31708575) Front Microbiol. 2012 Apr 24;3:152. (PMID: 22536200) Sci Rep. 2016 Oct 27;6:36107. (PMID: 27786298) Nature. 2021 Sep;597(7875):274-278. (PMID: 33208941) Rev Invest Clin. 2020;72(4):188-197. (PMID: 33064686) Int J Cancer. 2017 Aug 15;141(4):664-670. (PMID: 28369882) ACS Nano. 2019 Nov 26;13(11):12671-12686. (PMID: 31589013) J Immunother. 2015 Feb-Mar;38(2):71-6. (PMID: 25658616) Nat Rev Cancer. 2002 Jan;2(1):59-65. (PMID: 11902586) J Hematol Oncol. 2020 Nov 11;13(1):153. (PMID: 33176869) Dent Clin North Am. 2018 Jan;62(1):111-120. (PMID: 29126488) FEMS Yeast Res. 2021 Apr 7;21(3):. (PMID: 33837785) Cancers (Basel). 2022 Aug 27;14(17):. (PMID: 36077696) Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. (PMID: 31848188) Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:59-72. (PMID: 29108943) Diagnostics (Basel). 2022 Aug 06;12(8):. (PMID: 36010256) Front Immunol. 2023 Apr 26;14:1105265. (PMID: 37180106) BMC Med. 2016 May 05;14:73. (PMID: 27151159) J Transl Med. 2018 May 29;16(1):142. (PMID: 29843811) Biomed Res Int. 2020 Jan 29;2020:6842963. (PMID: 32083131) Mol Clin Oncol. 2019 Jan;10(1):17-28. (PMID: 30655973) J Immunol Methods. 2021 Nov;498:113133. (PMID: 34480950) J Clin Med. 2021 Feb 12;10(4):. (PMID: 33673300) Cancer Immunol Immunother. 2022 Aug;71(8):2007-2028. (PMID: 34982184) Front Immunol. 2018 Apr 05;9:527. (PMID: 29675018) Oncoimmunology. 2013 Dec 1;2(12):e26968. (PMID: 24498562) Cells. 2021 Nov 10;10(11):. (PMID: 34831327) Obstet Gynecol. 2013 Apr;121(4):829-846. (PMID: 23635684) Cancer Biol Med. 2020 Nov 15;17(4):864-878. (PMID: 33299640) Nat Med. 2018 May;24(5):541-550. (PMID: 29686425) Head Neck Oncol. 2010 Jun 29;2:15. (PMID: 20587061) Pathology. 2022 Mar;54(2):184-194. (PMID: 34645567) Cancer Manag Res. 2021 Aug 04;13:6045-6053. (PMID: 34377023) Cell. 2015 Sep 10;162(6):1217-28. (PMID: 26321681) N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456) Biomedicines. 2021 Jan 09;9(1):. (PMID: 33435454) J Med Virol. 2023 Jan;95(1):e28144. (PMID: 36121194) Cancer Cell. 2020 Oct 12;38(4):454-472. (PMID: 32822573) Carcinogenesis. 2014 Jun;35(6):1267-75. (PMID: 24523449) Cell Mol Immunol. 2020 Aug;17(8):807-821. (PMID: 32612154) J Immunol Res. 2018 May 2;2018:2912671. (PMID: 29854832) Poult Sci. 2023 Jun;102(6):102662. (PMID: 37043959) BMC Womens Health. 2023 May 3;23(1):216. (PMID: 37138261) Front Immunol. 2022 Nov 21;13:1037124. (PMID: 36479105) J Immunother. 2000 Jul-Aug;23(4):412-8. (PMID: 10916750) Hum Vaccin Immunother. 2016 Jun 2;12(6):1418-29. (PMID: 26835746) Inflammation. 2016 Oct;39(5):1690-703. (PMID: 27422006) Curr Opin Immunol. 2006 Apr;18(2):206-13. (PMID: 16464564) Asian Pac J Cancer Prev. 2014;15(14):5909-16. (PMID: 25081721) Biochem J. 2011 Jun 1;436(2):351-62. (PMID: 21418037) Nat Commun. 2021 Aug 9;12(1):4791. (PMID: 34373452) Int J Cancer. 2017 Mar 1;140(5):1134-1146. (PMID: 27864932) Biomark Res. 2022 Dec 7;10(1):89. (PMID: 36476317) J Immunother Cancer. 2019 Oct 17;7(1):263. (PMID: 31623687) Int J Cancer. 2016 Sep 15;139(6):1358-71. (PMID: 27130719) Curr Probl Cancer. 2018 Sep;42(5):493-506. (PMID: 30041818) Front Cell Infect Microbiol. 2021 Apr 30;11:649815. (PMID: 33996630) Int J Mol Sci. 2020 Nov 05;21(21):. (PMID: 33167514) Nat Commun. 2019 Nov 27;10(1):5408. (PMID: 31776331) Cytokine. 2019 Aug;120:210-219. (PMID: 31121496) Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7. (PMID: 18760711) J Cancer. 2021 Apr 20;12(12):3501-3514. (PMID: 33995627) Biomed Pharmacother. 2018 Oct;106:1537-1556. (PMID: 30119229) World J Clin Oncol. 2014 Oct 10;5(4):753-63. (PMID: 25302175) Int J Mol Sci. 2020 Aug 20;21(17):. (PMID: 32825343) Immunol Lett. 2022 Jul;247:52-58. (PMID: 35577002) Curr Biol. 2020 Aug 17;30(16):R921-R925. (PMID: 32810447) Nat Rev Cancer. 2018 Jul;18(7):419-432. (PMID: 29695749) Front Oncol. 2021 Jun 10;11:673276. (PMID: 34178661) Cancer Lett. 2019 Aug 1;456:69-79. (PMID: 31055110) Cell Rep. 2018 Jan 2;22(1):27-35. (PMID: 29298428) N Engl J Med. 2022 Dec 8;387(23):2113-2125. (PMID: 36477031) Cancers (Basel). 2016 Aug 05;8(8):. (PMID: 27527216) Cancer Immunol Immunother. 2007 May;56(5):739-45. (PMID: 17195077) Nat Rev Immunol. 2011 Jul 25;11(8):519-31. (PMID: 21785456) Immunity. 2020 Jan 14;52(1):183-199.e9. (PMID: 31924475) Cancer Lett. 2021 Feb 28;499:279-289. (PMID: 33232788) Expert Opin Biol Ther. 2022 Apr;22(4):465-472. (PMID: 34654337) Eur Arch Otorhinolaryngol. 2013 Feb;270(2):711-8. (PMID: 22692695) Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532) J Clin Oncol. 2019 Oct 20;37(30):2759-2768. (PMID: 31408414) Front Oncol. 2022 Aug 10;12:910486. (PMID: 36033480) Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):276-82. (PMID: 9988787) Clin Cancer Res. 2009 Jul 1;15(13):4391-400. (PMID: 19549768) Oral Oncol. 2019 Mar;90:134-135. (PMID: 30665705) Cell Commun Signal. 2020 Apr 7;18(1):59. (PMID: 32264958) JCI Insight. 2018 Apr 19;3(8):. (PMID: 29669936) Front Pharmacol. 2022 May 24;13:868695. (PMID: 35685630) Lancet Glob Health. 2020 Feb;8(2):e191-e203. (PMID: 31812369) Tumour Virus Res. 2022 Jun;13:200238. (PMID: 35460940) Immunotargets Ther. 2020 Oct 07;9:167-200. (PMID: 33117742) Int J Mol Sci. 2019 Jul 05;20(13):. (PMID: 31284453) PLoS Pathog. 2013;9(5):e1003384. (PMID: 23717208) Viruses. 2019 Oct 09;11(10):. (PMID: 31600915) Cancer Discov. 2021 Aug;11(8):1896-1912. (PMID: 33990345) Lancet Oncol. 2017 Jun;18(6):803-811. (PMID: 28434660) Curr Pharm Des. 2005;11(27):3485-500. (PMID: 16248803) Front Oral Health. 2021 Feb 11;2:604565. (PMID: 35047989) JCI Insight. 2016 Oct 20;1(17):e89829. (PMID: 27777979) Cancer Cell Microenviron. 2016;3(4):. (PMID: 28133621) J Control Release. 2018 Mar 10;273:1-12. (PMID: 29355622) J Immunother Cancer. 2021 Aug;9(8):. (PMID: 34341131) Laryngoscope. 2016 Jun;126(6):1365-72. (PMID: 26707355) Blood. 2017 Apr 6;129(14):1991-2001. (PMID: 28143882) Cancers (Basel). 2021 Jan 26;13(3):. (PMID: 33530343) Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. (PMID: 30518633) Biomaterials. 2021 Nov;278:121161. (PMID: 34601198) Cancers (Basel). 2021 Nov 23;13(23):. (PMID: 34884999) Front Med (Lausanne). 2022 Jun 30;9:932196. (PMID: 35847783) Mol Immunol. 2019 Apr;108:102-110. (PMID: 30802787) Mol Cancer. 2022 Feb 11;21(1):45. (PMID: 35148751) Diagnostics (Basel). 2023 Jan 09;13(2):. (PMID: 36673053) JAMA Oncol. 2018 Jul 12;4(7):e173776. (PMID: 29145543) Viruses. 2023 Jan 10;15(1):. (PMID: 36680237) J Virol. 2008 Feb;82(4):1968-79. (PMID: 18057249) Eur J Cancer. 2014 Nov;50(16):2846-54. (PMID: 25155250) Chin J Cancer. 2011 May;30(5):344-50. (PMID: 21527067) Front Immunol. 2020 Feb 19;11:60. (PMID: 32140153) J Clin Oncol. 2022 Jun 1;40(16):1795-1805. (PMID: 35192397) Cancers (Basel). 2022 Apr 13;14(8):. (PMID: 35454882) J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34083421) Infect Dis Clin North Am. 2013 Dec;27(4):765-78. (PMID: 24275269) Stem Cells Int. 2022 Aug 15;2022:5775696. (PMID: 36004381) Lancet. 2015 Nov 21;386(10008):2078-2088. (PMID: 26386540) Oncol Rep. 2020 Aug;44(2):698-710. (PMID: 32627036) Nat Rev Cancer. 2010 Aug;10(8):550-60. (PMID: 20592731) Int J Cancer. 2013 Sep 1;133(5):1187-96. (PMID: 23436563) Pak J Biol Sci. 2018;21(3):135-150. (PMID: 30187723) Cancers (Basel). 2023 May 11;15(10):. (PMID: 37345057) Clin Cancer Res. 2018 Aug 1;24(15):3644-3655. (PMID: 29669806) Nat Rev Cancer. 2023 Mar;23(3):173-188. (PMID: 36456755) Nat Rev Dis Primers. 2016 Dec 01;2:16086. (PMID: 27905473) Clin Cancer Res. 2009 Feb 1;15(3):778-87. (PMID: 19188147) Cancer Cell. 2022 Sep 12;40(9):1010-1026.e11. (PMID: 36027916) Nat Biomed Eng. 2018 Aug;2(8):578-588. (PMID: 31015631) Mutagenesis. 2010 Mar;25(2):149-54. (PMID: 19892774) Oral Dis. 2020 Oct;26(7):1384-1392. (PMID: 32315470) Oncoimmunology. 2016 Mar 10;5(6):e1147641. (PMID: 27471615) Hum Immunol. 2012 Sep;73(9):920-6. (PMID: 22749886) J Cancer Res Clin Oncol. 2023 May;149(5):2115-2138. (PMID: 35925428) Cancer Med. 2020 Feb;9(3):1008-1016. (PMID: 31851776) Cancers (Basel). 2018 Dec 28;11(1):. (PMID: 30597841) J Clin Oncol. 2015 May 10;33(14):1543-50. (PMID: 25823737) Front Pharmacol. 2021 Aug 20;12:720692. (PMID: 34489708) Nat Rev Drug Discov. 2015 Sep;14(9):642-62. (PMID: 26323545) Front Immunol. 2023 Feb 03;14:1094437. (PMID: 36817443) N Engl J Med. 2006 Feb 9;354(6):567-78. (PMID: 16467544) Clin Cancer Res. 2021 Feb 1;27(3):689-703. (PMID: 33122346) Breast Cancer Res. 2016 Aug 11;18(1):84. (PMID: 27515302) J Interferon Cytokine Res. 2019 Jan;39(1):6-21. (PMID: 29889594) Open Virol J. 2012;6:204-15. (PMID: 23341856) Immunity. 2018 Mar 20;48(3):417-433. (PMID: 29562193) Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. (PMID: 34112709) Nat Med. 1996 Jan;2(1):52-8. (PMID: 8564842) Gynecol Oncol. 2006 Jul;102(1):22-31. (PMID: 16427684) Front Immunol. 2021 Mar 09;12:636568. (PMID: 33767702) Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344) |
| معلومات مُعتمدة: | Bolsa Produtividade 308489/2019-5 National Council for Scientific and Technological Development; CNPq/MCTI/CT-BIOTEC Nº 31/2022, grant number 440315/2022-0 National Council for Scientific and Technological Development; APQ-1482-2.02/22 - Apoio a Fixação de Jovens Doutores em Pernambuco Fundação de Amparo à Ciência e Tecnologia de Pernambuco |
| فهرسة مساهمة: | Keywords: APC; TAM; TME; cell therapy; papillomavirus; vaccines |
| تواريخ الأحداث: | Date Created: 20230826 Latest Revision: 20230829 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10458729 |
| DOI: | 10.3390/vaccines11081354 |
| PMID: | 37631922 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2076-393X |
|---|---|
| DOI: | 10.3390/vaccines11081354 |